Clinical bottom line
Corticosteroids are the primary treatment for sudden sensorineural hearing loss (SSNHL), a condition characterized by rapid onset hearing loss with no identifiable cause. Both systemic and intratympanic corticosteroid therapies have been shown to improve hearing outcomes, though the optimal strategy remains debated. Current evidence suggests that early intervention, ideally within two weeks of symptom onset, maximizes the likelihood of hearing recovery. Individualized treatment plans should consider patient-specific factors, including severity of hearing loss and potential contraindications to systemic corticosteroids.
What the evidence shows
Systemic corticosteroids, such as oral prednisone, have long been the standard initial treatment for SSNHL. A systematic review by Crane et al. (2015) supports their use, demonstrating improved hearing recovery compared to placebo [PMID: 25991470]. The recommended regimen typically involves high-dose oral corticosteroids tapered over a period of 10-14 days.
Intratympanic corticosteroid therapy, involving direct administration of steroids into the middle ear, has gained popularity as an alternative or adjunctive treatment. The HEAL study (2014) compared intratympanic dexamethasone to oral prednisone and found no significant difference in hearing outcomes, suggesting intratympanic therapy as a viable option for patients who cannot tolerate systemic steroids [PMID: 24604102].
Combination therapy, using both systemic and intratympanic corticosteroids, has been investigated for potentially superior outcomes. A meta-analysis by Wei et al. (2017) indicated that combination therapy might offer a modest improvement in hearing recovery compared to systemic therapy alone, though the effect size was small [PMID: 28095074].
Caveats and uncertainty
While corticosteroid therapy is generally well-tolerated, systemic steroids can cause side effects such as hyperglycemia, hypertension, and mood changes, necessitating careful patient selection and monitoring. Intratympanic therapy, while minimizing systemic exposure, carries risks of tympanic membrane perforation and transient vertigo.
The variability in individual responses to corticosteroid therapy and the spontaneous recovery rate of SSNHL complicate the assessment of treatment efficacy. The optimal timing, dosage, and duration of corticosteroid therapy remain areas of ongoing research, with no consensus on a standardized protocol.
Further studies are needed to identify biomarkers that predict response to treatment and to explore the role of adjunctive therapies, such as hyperbaric oxygen or antiviral agents, in enhancing recovery.
How this may change practice
The evolving evidence on corticosteroid strategies in SSNHL highlights the importance of early intervention and individualized treatment plans. Clinicians should consider both systemic and intratympanic corticosteroid options, tailoring therapy based on patient-specific factors and preferences.
As research continues to refine our understanding of SSNHL management, treatment guidelines may evolve to incorporate combination therapies and novel adjunctive treatments. Clinicians should remain informed about the latest evidence to optimize patient outcomes and minimize the impact of SSNHL on quality of life.